See more : Tokyo Rakutenchi Co.,Ltd. (8842.T) Income Statement Analysis – Financial Results
Complete financial analysis of Entrada Therapeutics, Inc. (TRDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Entrada Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Purthanol Resources Limited (PURT) Income Statement Analysis – Financial Results
- Chung Hwa Food Industrial Co., Ltd. (4205.TWO) Income Statement Analysis – Financial Results
- HEC Infra Projects Limited (HECPROJECT.NS) Income Statement Analysis – Financial Results
- United World Holding Group Ltd. (UWHGF) Income Statement Analysis – Financial Results
- CarbonMeta Technologies, Inc. (COWI) Income Statement Analysis – Financial Results
Entrada Therapeutics, Inc. (TRDA)
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 129.01M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 99.88M | 1.90M | 1.12M | 326.00K | 104.00K |
| Gross Profit | 29.13M | -1.90M | -1.12M | -326.00K | -104.00K |
| Gross Profit Ratio | 22.58% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 99.88M | 66.61M | 35.93M | 21.10M | 8.22M |
| General & Administrative | 32.29M | 30.64M | 15.20M | 5.57M | 3.61M |
| Selling & Marketing | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.29M | 30.64M | 15.20M | 5.57M | 3.61M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 6.27M |
| Operating Expenses | 132.18M | 97.25M | 51.13M | 26.67M | 11.82M |
| Cost & Expenses | 132.18M | 97.25M | 51.13M | 26.67M | 11.82M |
| Interest Income | 15.22M | 2.63M | 0.00 | 144.00K | 451.00K |
| Interest Expense | 0.00 | 2.63M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.84M | 1.90M | 1.12M | 326.00K | 104.00K |
| EBITDA | -321.00K | -95.35M | -50.01M | -26.34M | -11.72M |
| EBITDA Ratio | -0.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.16M | -97.25M | -51.13M | -26.67M | -11.82M |
| Operating Income Ratio | -2.45% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 15.22M | 2.63M | -31.00K | 144.00K | 6.72M |
| Income Before Tax | 12.06M | -94.62M | -51.16M | -26.52M | -5.10M |
| Income Before Tax Ratio | 9.34% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 18.74M | -7.16M | -1.09M | -144.00K | -451.00K |
| Net Income | -6.69M | -87.46M | -50.07M | -26.38M | -4.65M |
| Net Income Ratio | -5.18% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.20 | -2.79 | -1.60 | -0.84 | -0.15 |
| EPS Diluted | -0.20 | -2.79 | -1.60 | -0.84 | -0.15 |
| Weighted Avg Shares Out | 33.05M | 31.29M | 31.22M | 31.25M | 31.25M |
| Weighted Avg Shares Out (Dil) | 33.05M | 31.29M | 31.22M | 31.25M | 31.25M |
Entrada Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced it will...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA
NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA
NEW YORK , Nov. 29, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are advised to contact Robert S.
Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug
Despite providing additional information, the FDA declines to lift the clinical hold on Entrada's (TRDA) regulatory filing seeking approval to start studies on its DMD drug in the United States.
Entrada Therapeutics shares tumble as FDA refuses to lift hold on muscular dystrophy trial
Entrada Therapeutics shares plummeted almost 30% after it announced that the U.S. Food and Drug Administration (FDA) has refused to lift its clinical hold on its Phase 1 study of its investigational therapeutic ENTR-601-44 for Duchenne muscular dystrophy.
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
– Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 – – ENTR-601-44 clinical development program remains on track with data readout expected in second half of 2024 – – U.S. FDA clinical hold on...
Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of a loss of $0.55 per share. This compares to loss of $0.80 per share a year ago.
Entrada Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced it will...
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
– Initiation of Phase 1 clinical trial marks Entrada's transition into a clinical company – – Data anticipated in the second half of 2024 – BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company...
Entrada Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the Company will...
Source: https://incomestatements.info
Category: Stock Reports